Today we’re taking a moment to say a huge THANK YOU to #TeamApellis. 🧡 Your dedication, hard work, and passion are our driving force. Together, we’re transforming what’s possible for patients. #WeAreApellis
Apellis Pharmaceuticals
Biotechnology Research
Waltham, MA 89,794 followers
Global biopharma company leveraging courageous science, creativity, and compassion to deliver life-changing therapies.
About us
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
- Website
-
https://apellis.com/
External link for Apellis Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Waltham, MA
- Type
- Public Company
- Founded
- 2008
- Specialties
- Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
Locations
-
Primary
Get directions
100 Fifth Ave
3rd Floor
Waltham, MA 02451, US
-
Get directions
720 Market Street
5th Floor
San Francisco, California 94102, US
-
Get directions
Zählerweg 10
Zug, 6300, CH
Employees at Apellis Pharmaceuticals
-
Natalya Gromyko
Biopharma New Product Planning Leader | Strategic Insights | R&D Collaboration | Launch Experience | Clinical and Commercial Strategy and Insights
-
Renaud Desgraz, PhD
-
Kira Tsivkin
-
Lisa Paul-Stark
Patient focused rare disease medical sales professional with over 20 years of success, including more than 18 years in rare/Orphan disease, focusing…
Updates
-
#TeamApellis is tremendously grateful to all the caregivers who provide physical, emotional, and everyday support to their friends and family. As we deliver treatments and advance new possibilities for people living with serious diseases, we remain committed to learning from and standing with the caregiver community. We honor you this #NationalFamilyCaregiversMonth. #WeAreApellis #NFCM
-
-
We were honored to be a part of The Royal Australian and New Zealand College of Ophthalmologists (RANZCO) 56th Annual Scientific Congress in Melbourne last weekend, bringing together the ophthalmology community to advance understanding and care for #GeographicAtrophy (GA). We’re grateful to our ophthalmology colleagues, speakers, and attendees for your dedication to improving patient outcomes. Together, we’re working to drive meaningful change in the lives of those affected by vision loss. #WeAreApellis #RANZCO56th
-
-
Spotlight on Robyn Malofy! We’re proud to support and celebrate employees who grow their careers by taking on new challenges within Apellis. Robyn offers her advice for anyone ready to embrace new experiences. Learn more about how we support professional growth and browse our open positions: http://bit.ly/4ntHr51 #WeAreApellis
-
-
We’re pleased to share new five-year data from our GALE extension study in geographic atrophy (GA). In a post hoc-analysis, data showed that our medicine delayed disease progression by ~1.5 years in patients with nonsubfoveal GA. Read more: http://bit.ly/49eQUtF #WeAreApellis
-
-
Our CEO Cedric Francois had the privilege of speaking on a panel at the recent #PrixGalien USA Forum, hosted by The Galien Foundation in New York. We are inspired to be part of an industry advancing scientific innovation to improve human health across the world! #WeAreApellis
-
-
Apellis is proud to have delivered the first approved therapy for people 12 and older living with C3G and primary IC-MPGN by harnessing our world-class expertise in complement science. Attending American Society of Nephrology #KidneyWk? Stop by booth #105 to learn how targeting C3 can make a meaningful difference for patients with these rare kidney diseases. #WeAreApellis
-
Attending American Society of Nephrology #KidneyWk? Visit us at booth #516 to learn more about how we’re transforming the treatment of rare kidney diseases. We hope to see you there! Get a sneak preview of our booth below. #WeAreApellis
-
We’re looking forward to the American Society of Nephrology Kidney Week meeting! #TeamApellis will share 7 presentations, including an oral presentation on new data from our Phase 3 VALIANT study in C3G and primary IC-MPGN, reinforcing our treatment’s robust efficacy over a year. Learn more: http://bit.ly/4qx82Rp #KidneyWk #WeAreApellis
-
-
At Apellis, we advance courageous science to deliver life-changing medicines for some of the most challenging diseases patients face. Our researchers have studied complement for over 20 years and are leading the field in targeted C3 therapies. Learn more about our revolutionary science at https://bit.ly/45NXkLy #WeAreApellis
-